Patients often get insufficient information on their health condition and treatment and virtually have no influence on the development of improved drugs and therapies. This will change with EUPATI, the ‘European Patients’ Academy on Therapeutic Innovation’. EUPATI is going to launch its national platform in Luxembourg and organises an encounter on 17th December 2014 to inform key stakeholders and the press.
EUPATI promotes ‘patient empowerment’ because it believes that well informed patients can substantially impact and boost therapeutic innovation. Its objective is thus to educate patients, patient associations, advocacy leaders and the lay public, and to enable patients and their representatives to become efficient advisors in medicine R&D. To these ends, EUPATI develops and provides targeted, comprehensive and scientifically reliable educational material on translational science topics such as drug development, clinical trial design and personalised medicine.
The EUPATI initiative was started in 2012 by the European Commission, involves twelve European countries and is funded by the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative intended to speed up drug development. The highly collaborative project is led by key pan-European patient associations. It receives strong input from a range of academic partners, research organisations, not-for-profit organisations and pharmaceutical industries. At the national level it is coordinated by National Liaison Teams.
EUPATI Luxembourg invites patients and patient organisations to join its platform. A special webpage for Luxembourg was created to share news and give access to the already available educational material. News are also broadcasted via social media: on Facebook and Twitter .
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.